Relationship between PD-L1 expression and prognostic factors in high-risk cutaneous squamous and basal cell carcinoma


Yülek Ö., BATUR Ş., Özcan K., Yol C., Ülgen Ö. A.

Bosnian Journal of Basic Medical Sciences, vol.22, no.6, pp.894-900, 2022 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 6
  • Publication Date: 2022
  • Doi Number: 10.17305/bjbms.2022.7574
  • Journal Name: Bosnian Journal of Basic Medical Sciences
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.894-900
  • Keywords: basal cell carcinoma, Cutaneous squamous cell carcinoma, PD-L1
  • Çanakkale Onsekiz Mart University Affiliated: No

Abstract

This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) and its relationship with prognostic factors in tumors that are not in the head and neck region and are therefore relatively less exposed to the sun. This retrospective cross-sectional study included 25 invasive cSCC and 42 BCC cases with a diameter ≥2 cm located outside the head and neck region from 2010 to 2018. The biopsy samples were examined based on the membranous PD-L1 (22C3 clone) staining. Staining results were scored as follows: 0, no staining (negative); 1, <10% PD-L1 positivity of tumor cells; and 2, ≥10% PD-L1 positivity of tumor cells. PD-L1 positivity was not seen in any BCC cases, whereas 11 (44%) of cSCC cases were PD-L1 positive. No significant relationship was observed between PD-L1 expression and prognostic parameters, including tumor diameter, tumor depth, and lymphovascular or perineu-ral invasion in the cSCC group. PD-L1 expression was not associated with prognostic factors in the early stages of BCC and SCC located outside the head and neck region. Therefore, investigating the PD-L1 expression seems to be more relevant in patients with advanced-stage disease.